Exhausted by the endless rumors, etc., we decided to do a search of our own:

http://www.townsendletter.com/Dec2002/artemisinin1202.htm (secondary source).

http://www.drlam.com/A3R_brief_in_doc_format/Artemisinin.cfm (secondary source showing higher dosing than ours)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
pubmed&list_uids=8730315&dopt=Citation (primary source, dosage for malaria a bit less than our dosing suggestions)

http://www.blackwell-synergy.com/doi/pdf/10.1046/j.1365-2125.1998.t01-1-00686.x
Safety study for artemisinin showing it is safe for children as young as 2 years old.

http://www.google.com/search?q=artemisinin+children&ie=
utf-8&oe=utf-8&aq=t&rls=org.mozilla:en-US:official&client=firefox-a
Google search showing safety indication, including indications in children.

These reports on safety in children deserve special mention. We know ART functions as an agent that kills--or stuns--HPV. If the level of HPV-cytotoxic activity is high enough, however, inflammation will result, potentially causing airway obstruction in very young children. This could be life-threatening and would not be reported in safety literature on kids without RRP because they don't have chronic HPV/RRP infections. Anyone using ART with kids needs to be especially careful. Physician supervision and close monitoring is absolutely indicated and required. We don't know if there will be inflammation or how serious it could be in kids with RRP. RRP ISA is not "recommending" any treatments, including ART, and we are adding a cautionary comment with respect to the use of ART in infants, toddlers and young children who, almost by definition, have very small airways.

http://tropej.oxfordjournals.org/cgi/content/full/52/2/78
World Health Organization (WHO) report showing safety in children with minimal side-effects, including neurological, even for analogues of ART.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=
PubMed&list_uids=12435450&dopt=Abstract
At HISH doses, artemisinin derivatives can be neurotoxic but toxicity has not been found in clinical studies. The mechanism of neurotoxicity may be similar to the mechanism of action.

http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/95vol21/
21s3/21s3q_e.html
Artemisinin derivatives have been used in over 1 million patients and are well tolerated. Animal studies suggest toxicity in the liver, kidney, bone marrow, heart and central nervous system. To date, there have been two human cases of complete heart block associated with the use of artemisinin but most volunteer and clinical studies have found no evidence of cardiotoxicity. Neurologic lesions involving the brainstem have been seen in rats, dogs, and more recently in primates [unpublished] given repetitive doses of artemisinin derivatives. To date no clinical neurologic events have been observed in humans but no studies have addressed cumulative toxicity in humans. The safety of qinghaosu derivatives in pregnancy has not been established.

http://www3.interscience.wiley.com/cgi-bin/abstract/112131058/
ABSTRACT?CRETRY=1&SRETRY=0
Toxic brainstem encephalopathy after artemisinin treatment for breast cancer

http://www.ugc.edu.hk/rgc/rgcnews12/Pages/6%20Malaria-E.html
“The same fatty layers repel water so, by making the drug more hydrophilic, it doesn’t really want to go through the fatty membrane.” It is also important that the compound does not break down in the body to dihydroartemisinin. [RRP ISA: This could be a problem in RRP, since DHA is what we WANT]

http://www.rbm.who.int/cmc_upload/0/000/014/923/am2_1-8.htm (primary +secondary)
There is no clinical evidence to date of serious neurotoxicity resulting from the use of any artemisinin drug in humans in prospective studies of more than 10 000 patients or in the more than 2 million persons who have received these drugs (234, 235).